Results 21 to 30 of about 1,814 (132)

Brolucizumab for Neovascular Age-Related Macular Degeneration in Real-World Setting

IJRETINA (International Journal of Retina), 2023
Introduction: The mainstay treatment for neovascular AMD (nAMD) is intravitreal injections of anti-vascular growth factor (anti-VEGF) agents. Based on clinical trials, a newly developed anti-VEGF named brolucizumab showed noninferiority in anatomical and
Andi Marsa Nadhira, Ari Djatikusumo, Andi Arus Victor   +2 more
doaj   +1 more source

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

Case Reports in Ophthalmology, 2022
The efficacy of intravitreal anti-VEGF may be reduced in vitrectomized eyes due to accelerated drug clearance. Given its longer durability, brolucizumab may represent a suitable therapeutic option.
Emilia Maggio, Alessandro Alfano, Maurizio Mete, Grazia Pertile   +3 more
doaj   +1 more source

Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER

Ophthalmology and Therapy, 2023
Introduction The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration.
Ramin Tadayoni, Glenn J. Jaffe, Frank G. Holz, Ursula Schmidt-Erfurth, Kanji Takahashi, Chui Ming Gemmy Cheung, Seenu M. Hariprasad, Kinfemichael Gedif, Rasmus Olsen, Catherine Best, Franklin Igwe, Peter K. Kaiser   +11 more
doaj   +1 more source

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration

Frontiers in Pharmacology, 2022
Purpose: To assess the morphological and functional outcomes within the first year of treatment with intravitreal brolucizumab for refractory neovascular age-related macular degeneration (nAMD).Methods: This retrospective study included 21 eyes from 19 ...
Alaa Din Abdin, Wissam Aljundi, Khalil El Jawhari, Shady Suffo, Isabel Weinstein, Berthold Seitz   +5 more
doaj   +1 more source

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization

Scientific Reports, 2022
We evaluated 1-year outcomes of loading phase treatment followed by maintenance treatment using a treat-and-extend (TAE) regimen with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) associated with type 1 macular ...
Hidetaka Matsumoto, Junki Hoshino, Ryo Mukai, Kosuke Nakamura, Hideo Akiyama   +4 more
doaj   +1 more source

High-Yield Biosynthesis Process and Characterization of Brolucizumab

Pharmaceutical Fronts
Brolucizumab was the first single-chain fragment variable (scFv) antibody approved by the FDA for the treatment of age-related macular degeneration (AMD). However, the manufacturing process of brolucizumab remains rarely reported.
Xiaoyue Hu, Shuaiyi Huang, Tao Luo, Yapeng Wang, Jianguang Lu, Jun Feng   +5 more
doaj   +1 more source

Intraocular inflammation secondary to intravitreal brolucizumab treated successfully with Sub-Tenon triamcinolone: A case report

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report on a case of successful treatment of intraocular inflammation (IOI) secondary to brolucizumab intravitreal injection that responded to a single sub-Tenon injection of triamcinolone.
Shree K. Kurup, Tarek Tabbaa, Jose J. Echegaray, Armando L. Oliver   +3 more
doaj   +1 more source

Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis

Clinical Ophthalmology, 2023
Nicholas J Saba,1 Scott D Walter2 1Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY, USA; 2Retina Consultants, PC, Hartford, CT, USACorrespondence: Scott D Walter, Retina Consultants, PC, 43 Woodland Street, Hartford, CT, USA ...
Saba NJ, Walter SD
doaj  

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents

Clinical Ophthalmology, 2023
Joseph M Coney,1 Jasmyne E McCoy,1 Samriddhi Buxy Sinha,2 Nina Sonbolian,2 Lujia Zhou,3 Thomas P Hull,1 Shawn A Lewis,1 David G Miller,1 Michael A Novak,1 Scott D Pendergast,1 Hang Pham,1 Sean M Platt,1 Llewelyn J Rao,1 Jerome P Schartman,1 Lawrence J ...
Coney JM, McCoy JE, Buxy Sinha S, Sonbolian N, Zhou L, Hull TP, Lewis SA, Miller DG, Novak MA, Pendergast SD, Pham H, Platt SM, Rao LJ, Schartman JP, Singerman LJ, Donkor R, Fink M, Zubricky R, Karcher H   +18 more
doaj